Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Comparison of treatments was performed on a within-subject level (each mouse was its own control) and at least 1 week elapsed between each testing condition (drug or control treatment)
That was one of the things we worried about
/sc-assets/prd/practices/cdcd65da-a892-465a-aa2c-48d5c1f8134f/Tirzepatide%20vial.png)
Patients with a personal or family history of medullary thyroid carcinoma, patients with Multiple Endocrine Neoplasia syndrome type 2, patients who are pregnant or planning to become pregnant, and patients with certain gastrointestinal conditions may not be eligible
There is more on the line than wasted money
FDA approval timeline June 2023 : Phase 2 results in the New England Journal of Medicine 17.5% weight loss at 24 weeks December 2025 : TRIUMPH-4 results 28.7% weight loss March 2026 : TRANSCEND-T2D-1 results glycemic control + weight loss May 2026 : TRIUMPH-1 results up to 28.3% / 70 lbs over 80 weeks Late 2026 (est.) : Remaining TRIUMPH trials complete
US$ 22.81
US$ 25.97
US$ 22.06
US$ 24.14
US$ 21.42
US$ 21.49
US$ 21.29
